Mortality-based definition of renal hyperfiltration in middle-aged men: a 35-year cohort from Finland

Mounir Ould Setti1,2 · Salah Eddine Oussama Kacimi3 · Leo Niskanen4 · Tomi-Pekka Tuomainen1

Received: 1 July 2021 / Accepted: 24 October 2021 / Published online: 3 November 2021
© The Author(s) 2021

Abstract

Background While the impact of low glomerular filtration rate (eGFR) on various outcomes has been extensively studied, the other adverse occurrence, renal hyperfiltration (RHF), remains understudied, poorly defined, and, therefore, its impact on mortality unestablished.

Methods Using a population-based subcohort from the Kuopio Ischaemic Disease Risk Factor Study restricted to non-diabetic Finnish men aged 54 or 55 years, we followed up \( n = 1179 \) study participants for up to 35 years. We evaluated the hazard of all-cause mortality associated to RHF at different cutoff points defining eGFR. Based on models’ accuracy we suggested an optimal eGFR cutoff point for the definition of RHF. We divided the RHF category to three subgroups and evaluated them in terms of baseline characteristics and mortality hazard.

Results The eGFR value of 97 mL/min/1.73 m² corresponded to the models with the highest accuracy. Overall RHF associated with an increased risk of mortality (hazard ratio [HR] 1.42; 95% confidence interval [CI] 1.21 to 1.67). Moderate RHF associated with a decreased HR of mortality when compared to mild (0.64; 95% CI 0.46 to 0.9) or to extreme RHF (0.61; 95% CI 0.43 to 0.85), suggesting a rather U-shaped relationship between RHF’s eGFR values and mortality hazard.

Conclusion The burden of increased eGFR within what is still considered normal eGFR category was highly underestimated. RHF’s eGFR values had a U-shaped association with the risk of overall mortality. A more uniform consensual definition of RHF is needed, as higher to normal eGFR values that are not without consequences.

Keywords Mortality · Glomerular filtration rate · Renal hyperfiltration

Introduction

Glomerular filtration rate (GFR) stands as a key marker of renal function and an important predictor of morbimortality. Lower than normal GFR levels are known to be associated with cardiovascular disease and mortality, partly through kidney damage in chronic kidney disease (CKD) [1]. Higher than normal GFR, also termed renal hyperfiltration (RHF), has also been associated with CKD [2] and some conditions such as hypertension and diabetes mellitus [3], but its independent association with the overall risk of mortality has only been recently established [4, 5]. While the exact mechanism associating RHF to mortality is not yet determined, RHF has been proposed as potentially associated with low-grade systemic inflammation, oxidative stress, and thus, cardio renal metabolic risk [6]. At any rate, higher than normal GFR association with mortality is not without consequence. Nevertheless, a definition distinguishing RHF from normal GFR is strikingly absent from the literature.

GFR estimation is subject to inaccuracy as it is, in most studies, indirectly estimated from serum creatinine concentration which can be influenced by diet and muscle mass. GFR varies also according to gender and ethnicity, and declines naturally with aging [7]. While the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method is emerging as the standard for clinical estimation of GFR, studies use a variety of methods to estimate GFR based on
interest, expressed as units of mL/min/1.73 m² [15, 16]. The method, we computed the eGFR, our main exposure of baseline serum creatinine adjusted according to the Jaffe study nurse [14]. Based on the CKD-EPI equation and using by a physician, and interviewed and blood-sampled by a study nurse [13]. Different levels of eGFR within the RHF category might have distinct effects on health and could indicate subtypes of RHF with possible contrasting physiopathological and clinical characteristics. The purpose of this study was (i) to determine an optimal definition of RHF, in a population restricted to non-diabetic Finnish men of the same age (54 to 55 years), by investigating the long-term hazard of all-cause mortality associated to RHF defined using different cutoff values of GFR, and (ii) to evaluate the risk of mortality within subgroups of RHF.

Methods

Data source and variable measurement

Our study is based on a subcohort of 1592 Finnish men from the population-based Kuopio Ischaemic Heart Disease Risk Factor Study who were aged 54 or 55 years during their baseline examination between 1984 and 1989. After excluding subjects with diabetes at baseline (n = 107), subjects who reported abstinence from alcohol consumption during the year preceding study enrollment (n = 239), outliers (n = 8), and subjects with missing values, we settled for n = 1179 men who were then followed up for a median of 27 years and a maximum of 35 years in which their status of health was annually assessed. There was no loss to follow-up among the study participants.

At baseline, the participants were physically examined by a physician, and interviewed and blood-sampled by a study nurse [14]. Based on the CKD-EPI equation and using baseline serum creatinine adjusted according to the Jaffe method, we computed the eGFR, our main exposure of interest, expressed as units of mL/min/1.73 m² [15, 16]. The eGFR cutoff to define RHF was a function of a sensitivity analysis. We set 60 mL/min/1.73 m² as the cutoff value of eGFR to separate the normal from the low eGFR category. A sensitivity analysis also considered 77 mL/min/1.73 m² as an eGFR cutoff value of separating the normal from the low eGFR category as recommended for our population’s age category by HUS, the largest health care provider in Finland [17]. The cause-of-death registry provided information on our outcome of interest: all-cause mortality.

Data analysis

By means of R version 4.0.3 (https://www.R-project.org) we built crude and adjusted (for baseline body mass index (BMI) [18], smoking [current, previous, never smoker] [19], BMI-smoking interaction [20], alcohol consumption [gram per week] [21], vitamin D level [22] [deficiency defined as values below the 10th percentile corresponding to 23.08 nmol/L], and hypertension [defined as a positive history of hypertension, anti-hypertensive medication, or a mean blood pressure ≥ 140/90 mmHg]) Cox proportional hazard models evaluating the risk of mortality associated to RHF in comparison to the normal eGFR category. We defined the period at risk as the time from enrollment to death or to 31 December 2018.

We performed a sensitivity analysis to define RHF based on different cutoff points of eGFR separating the normal eGFR category from the RHF category with eGFR cutoff points ranging from and including 90 [11] to 110.54 mL/min/1.73 m² (the 99.5 percentile) with a model each 0.1 mL/min/1.73 m². We constructed receiver operating characteristic curves for each of the models. Based primarily on their related area under the curve (AUC) and secondarily on the models’ R-squared values, we identified high accuracy models and suggested an optimal eGFR cutoff point for the definition of RHF.

In addition, we divided the RHF category (after defining an optimal eGFR cutoff point) to three equivalent subgroups (cuts at 33.33 and 66.66 percentiles among men with RHF): mild RHF, moderate RHF, and extreme RHF. Using crude and adjusted Cox proportional hazard models, we assessed the hazard of mortality associated to each of the RHF subgroups in comparison to (i) the normal eGFR category, (ii) mild RHF, and (iii) moderate RHF. Finally, we compared the participants’ characteristics across all categories of eGFR and across RHF subgroups using Chi-square and Kruskal–Wallis tests.

Results

We recorded 826 deaths during follow-up. Figure 1 illustrates changes of the AUC of adjusted and crude models by changes of the cutoff points defining RHF in these models.
The eGFR value of 97 mL/min/1.73 m² had the highest AUC in both adjusted (0.721; 95% confidence interval [CI] 0.693 to 0.750) and crude models (0.568; 95% CI 0.543 to 0.593). This result conformed with the R-squared plots of the crude and adjusted models (Fig. 2) and with the sensitivity analysis which set 77 mL/min/1.73 m² as the cutoff eGFR between the low and the normal eGFR categories. Therefore, we considered 97 mL/min/1.73 m² (77th percentile) as the optimal cutoff point between the normal eGFR and the RHF categories. Furthermore, the R-squared plots showed a second peak, slightly lower than the first, at around 103 mL/min/1.73 m² (93rd percentile) with a corresponding AUC of 0.716 (CI, 0.687 to 0.744), hinting that more than one RHF cutoff point could be relevant to mortality hazard estimation. Overall RHF associated with an increased risk of mortality (hazard ratio [HR] 1.42; 95% CI 1.21 to 1.67).

We found a relation of direct proportion between the RHF-associated hazard of mortality and the eGFR threshold of RHF after an initial steady phase, suggesting a possible biological gradient between high eGFR values and the...
long-term risk of mortality (supplementary material 1). To investigate this, we divided the RHF category (≥ 97 mL/min/1.73 m²) into three equivalent subgroups (cuts at 33.33 and 66.66 percentiles among men with RHF): mild (97 to 99.96 mL/min/1.73 m²), moderate (99.96 to 102.44 mL/min/1.73 m²), and extreme RHF (≥ 102.44 mL/min/1.73 m²); and compared them in term of baseline characteristics and hazard of overall mortality. The study participants did not differ in status of mortality, BMI, smoking status, or alcohol consumption across RHF subgroups although they differed across the ensemble of eGFR categories in respect to these characteristics (Table 1). Surprisingly, moderate RHF associated with a decreased hazard of mortality when compared to mild (HR, 0.64; 95% CI 0.46 to 0.89) or to extreme RHF (HR, 0.61; 95% CI 0.43 to 0.85), suggesting a rather U-shaped relationship between RHF’s eGFR values and the hazard of all-cause mortality (Figs. 3 and 4). The HRs of all-cause mortality are reported in supplementary material 2.

Discussion

Our study’s results can be summarized into two findings. The first one is that the optimal eGFR cutoff point for the definition of RHF could be much lower than the 95th percentile, often used to define RHF. After evaluating the 35-year hazard of all-cause mortality associated to high eGFR at a range of thresholds in 1187 non-diabetic Finnish men of the same baseline age, we estimated that the eGFR value of 97 mL/min/1.73 m² could serve as an optimal cutoff point for the definition of RHF in our study settings. This value represents the 77th percentile of eGFR in our study population, suggesting that usage of, for example, the 95th percentile of eGFR to define RHF [4, 23, 24] would underestimate the mortality burden attributed to RHF. In addition, this finding implies that the mortality risk attributed to low eGFR levels has also been mostly underestimated in the literature when compared to a reference category carrying its own part of mortality risk. The second finding of our study is the U-shaped association between RHF’s eGFR values and the hazard of overall mortality with an increased mortality risk at mild and extreme RHF subgroups. This finding suggests the existence of a multitude of subtypes of RHF possibly manifesting with different eGFR levels and leading to disparate prognoses.

RHF is a frequently observed phenomenon known to be favored by conditions such as diabetes, obesity, smoking, and hypertension [11]. RHF was long regarded as an early sign of CKD and diabetic nephropathy deterioration. While the physiopathology of RHF is unclear, especially beyond its association with diabetes, a growing body of research has recently established RHF as an independent predictor of mortality [4, 5]. Nonetheless, there is no consensual definition for RHF [11]. So far, RHF has been clinically defined using either percentile-based definitions or arbitrarily-set eGFR cutoffs. Cachat et al. noted in their systematic review that most of the studies of RHF had no control group in their choice of the eGFR cutoff point defining RHF, and to their surprise, similar eGFR thresholds were used across age-groups, even in pediatric studies, while it is established that eGFR varies considerably over time [9]. Without an outcome-based definition of RHF, the burden of the condition cannot be properly assessed, screened, or prevented, while as Donfrancesco et al. (2013) suggested, even small changes in eGFR could affect mortality risk [25]. Recently, Kim et al. (2020) [12] examined the effects of RHF, defined at different eGFR thresholds, on mortality in a population-based cohort. The authors found an increased hazard of mortality with RHF defined at eGFR cutoff values starting from 83.8 mL/min/1.73 m² in middle-aged men. This threshold corresponded to the 28th percentile of eGFR in this population. The association between RHF and mortality was statistically significant with eGFR values greater or equal than the 65th percentile, suggesting that up to 35% of Korean middle-aged men might be at increased risk of mortality due to RHF.

With an analogous design, we reached a similar conclusion as Kim et al.’s, that RHF is, in general, underestimated. Kim et al.’s clinically meaningful RHF threshold was, however, much lower than the one in our findings. Ethnicity could be an explanation of this difference, but more likely, our smaller sample size did not suffice to detect a significant effect on mortality at lower RHF thresholds. When it comes to the association between eGFR and mortality within the RHF category, our findings also differed from Kim et al. who did not note a heterogeneity in the relation between subgroups of RHF and death. Kim et al.’s findings were similar to Cox et al. (2008) who found an increased mortality risk in the higher RHF category in comparison to the lower one after dividing the RHF category into 2 subgroups [13]. In our study, we suggested a 3-subgroup division of the RHF category and found no difference in mortality risk between the lowest RHF category and the highest, but rather a U-shaped relation between mortality and eGFR levels within the RHF category.

With no loss to follow-up, our study benefited of a long follow-up time and a reliable assessment of the covariates and the mortality outcome. We restricted for age, gender, ethnicity, and the absence of diabetes and adjusted for smoking, obesity, the interaction between smoking and obesity, alcohol consumption, hypertension, and vitamin D deficiency. We found an association between RHF and increased mortality risk in both the crude and the adjusted models. Also, the ideal cutoff point of RHF was similar in the crude and adjusted models and when a more conservative eGFR cutoff point between the low and the normal
Table 1 Baseline characteristics and follow-up differences by estimated glomerular filtration rate (eGFR)

|                                         | Total       | Low eGFR (<60) \(^a\) | Normal eGFR (60 to 97) \(^b\) | Mild RHF (97 to 99.96) \(^b\) | Moderate RHF (99.96 to 102.44) \(^b\) | Extreme RHF (≥102.44) \(^b\) | Statistical test (all subgroups, n = 1187)\(^c\) | Statistical test (RHF subgroups, n = 269)\(^d\) |
|----------------------------------------|-------------|-------------------------|-------------------------------|-------------------------------|----------------------------------|-----------------------------|---------------------------------------------|---------------------------------------------|
| n                                      | 1187        | 22                      | 896                           | 90                            | 92                               | 87                          | Chi-square: df = 4, X² = 21.16, \(p < 0.001\) | Chi-square: df = 2, X² = 4.61, \(p = 0.1\) |
| Deaths (column %)                      | 826 (69.59) | 14 (63.64)              | 597 (66.63)                   | 74 (82.22)                    | 67 (72.83)                       | 74 (85.06)                  | Kruskal–Wallis: df = 4, H = 20.62, \(p < 0.001\) | Kruskal–Wallis: df = 2, H = 1.35, \(p = 0.51\) |
| Age in years                           | 54.42 [54.33, 54.50] | 54.50 [54.33, 54.50] | 54.42 [54.33, 54.50]         | 54.33 [54.17, 54.50]         | 54.33 [54.31, 54.42]             | 54.33 [54.33, 54.50]       | Kruskal–Wallis: df = 4, H = 20.62, \(p < 0.001\) | Kruskal–Wallis: df = 2, H = 1.35, \(p = 0.51\) |
| BMI (column %)                         |             |                         |                               |                               |                                 |                             | Chi-square: df = 4, X² = 27.08, \(p = 0.041\) | Chi-square: df = 8, X² = 12.12, \(p = 0.146\) |
| ≤25                                    | 373 (31.42) | 6 (27.27)               | 266 (29.69)                   | 26 (28.99)                    | 37 (40.22)                       | 38 (43.68)                  |                                            |                                             |
| (25, 27.5)                             | 365 (30.75) | 9 (40.91)               | 276 (30.80)                   | 27 (30.00)                    | 25 (27.17)                       | 28 (32.18)                  |                                            |                                             |
| (27.5, 30)                             | 253 (21.31) | 3 (13.64)               | 209 (23.33)                   | 20 (22.22)                    | 12 (13.04)                       | 9 (10.34)                   |                                            |                                             |
| (30, 32.5)                             | 126 (10.61) | 4 (18.18)               | 95 (10.60)                    | 11 (12.22)                    | 12 (13.04)                       | 4 (4.60)                    |                                            |                                             |
| >32.5                                  | 70 (5.90)   | 0 (0.00)                | 50 (5.58)                     | 6 (6.67)                      | 6 (6.52)                         | 8 (9.20)                    |                                            |                                             |
| Smoking status (column %)              |             |                         |                               |                               |                                 |                             | Chi-square: df = 8, X² = 2.22, \(p = 0.001\) | Chi-square: df = 4, X² = 8.99, \(p = 0.061\) |
| Never smoker                           | 348 (29.32) | 9 (40.91)               | 284 (31.70)                   | 25 (27.18)                    | 19 (20.65)                       | 11 (12.64)                  |                                            |                                             |
| Previous smoker                        | 430 (36.23) | 9 (40.91)               | 329 (36.72)                   | 33 (36.67)                    | 31 (33.70)                       | 28 (32.18)                  |                                            |                                             |
| Current smoker                         | 409 (34.46) | 4 (18.18)               | 283 (31.58)                   | 32 (35.56)                    | 42 (45.65)                       | 48 (55.17)                  |                                            |                                             |
| Alcohol consumption in g/week          | 40.80 [11.80, 96.68] | 18.62 [54.33, 86.03] | 38.45 [11.93, 94.95]         | 45.40 [14.48, 104.81]        | 48.00 [10.00, 103.69]            | 51.00 [11.90, 108.15]       | Kruskal–Wallis: df = 4, H = 4.76, \(p = 0.033\) | Kruskal–Wallis: df = 2, H = 0.51, \(p = 0.774\) |
| Hypertension (column %)                | 727 (61.25) | 15 (68.18)              | 559 (62.39)                   | 52 (57.78)                    | 53 (57.61)                       | 48 (55.17)                  | Chi-square: df = 4, X² = 32.26, \(p = 0.015\) | Chi-square: df = 2, X² = 15.12, \(p = 0.006\) |
| Vitamin D deficiency (column %)        | 119 (10.03) | 1 (4.55)                | 80 (89.3)                     | 7 (7.88)                      | 13 (14.13)                       | 18 (20.69)                  | Chi-square: df = 4, X² = 32.26, \(p = 0.015\) | Chi-square: df = 2, X² = 15.12, \(p = 0.006\) |
| eGFR in mL/min/1.73 m²                 | 85.17 [76.98, 96.83] | 56.65 [50.40, 58.65] | 81.95 [75.22, 88.57]         | 99.13 [98.57, 99.60]          | 100.80 [100.74, 101.92]          | 104.88 [103.64, 107.24]     | Kruskal–Wallis: df = 4, H = 67.40, \(p < 0.001\) | Kruskal–Wallis: df = 2, H = 23.87, \(p < 0.001\) |
| Follow-up in years                     | 27.42 [18.06, 32.03] | 26.23 [19.73, 32.48] | 28.54 [19.73, 32.48]         | 23.68 [14.97, 30.25]          | 25.66 [16.41, 32.41]             | 20.84 [10.33, 28.47]        | Kruskal–Wallis: df = 4, H = 37.47, \(p < 0.001\) | Kruskal–Wallis: df = 2, H = 8.41, \(p = 0.015\) |
| Age of death in years                  | 81.82 [72.44, 86.25] | 80.61 [63.52, 84.70] | 83.03 [74.05, 86.85]         | 77.97 [69.39, 84.61]          | 79.95 [70.87, 86.79]             | 75.17 [64.95, 82.96]        | Kruskal–Wallis: df = 4, H = 38.07, \(p < 0.001\) | Kruskal–Wallis: df = 2, H = 8.27, \(p = 0.016\) |

Numbers indicate median [interquartile range] unless otherwise indicated

BMI: body mass index in kg/m², eGFR: estimated glomerular filtration rate, RHF: renal hyperfiltration

\(^a\)In mL/min/1.73 m²

\(^b\)RHF subgroups were determined by cutoffs at 33.33 and 66.66 percentiles of men with RHF

\(^c\)Kruskal–Wallis rank-sum test and Pearson’s chi-squared test were used for across groups comparisons

\(^d\)Values concern RHF subgroups only: mild RHF, moderate RHF, and extreme RHF

\(^e\)Because of the low expected frequencies in some cells, Monte-Carlo simulation (based on 5 × 10⁵ replicates) was used to estimate \(p\)-value
The burden of increased eGFR within what is still considered normal eGFR category was highly underestimated. This could imply that the impact of low eGFR on mortality has also been underestimated. RHF’s eGFR values had a U-shaped association with the risk of overall mortality. A consensual definition of RHF is needed as higher to normal eGFR values are not without consequences.

Conclusion

The burden of increased eGFR within what is still considered normal eGFR category was highly underestimated. This could imply that the impact of low eGFR on mortality has also been underestimated. RHF’s eGFR values had a U-shaped association with the risk of overall mortality. A consensual definition of RHF is needed as higher to normal eGFR values are not without consequences.
**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s11255-021-03048-6](https://doi.org/10.1007/s11255-021-03048-6).

**Funding** Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.

**Data availability** The University of Eastern Finland can be approached for requests of access to the KIHD dataset.

**Declarations**

**Conflicts of interest** The authors declare they have no conflicts of interest.

**Ethical approval and licenses** The study protocol was approved by the Research Ethics Committee of the University of Eastern Finland and the Research Ethics Committee Hospital District of Northern Savo, Finland (no. 143/97), and each participant gave written informed consent. The KIHD Study was performed in accordance with the Declaration of Helsinki. Cause of Death registry—Statistics Finland (License TK-53-1770-16). Care Register for Healthcare—National Institute for Health and Welfare (License THL/93/5.05.00/2013).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet 375(9731):2073–2081
2. Oh SW, Yang JH, Kim M-G, Cho WY, Jo SK (2020) Renal hyperfiltration as a risk factor for chronic kidney disease: a health checkup cohort study. PLoS ONE. [https://doi.org/10.1371/journal.pone.0238177](https://doi.org/10.1371/journal.pone.0238177)
3. Sasson AN, Cherney DZ (2012) Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 3(1):1–6
4. Park M, Yoon E, Lim Y-H, Kim H, Choi J, Yoon H-J (2015) Renal hyperfiltration as a novel marker of all-cause mortality. J Am Soc Nephrol JASN 26(6):1426–1433
5. Penno G, Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R et al (2020) Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Res Care 8(1):e001481
6. Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, Lai V et al (2013) The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56(5):1166–1173
7. Glassock RJ, Winears C (2009) Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 120:419–428
8. Matsushita K, Mahmoodi BK, Woodward M, Emerson JR, Jafar TH, Jee SH et al (2012) Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307(18):1941–1951
9. Cachat F, Combescure C, Cauderay M, Girardin E, Chehade H (2015) A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. Clin J Am Soc Nephrol 10(3):382–389
10. Helal I, Fick-Brosnanan GM, Reed-Gitomer B, Schrier RW (2012) Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 8(5):293–300
11. Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A et al (2019) Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor for cardiovascular disease and mortality. Diabetes Obes Metab 21(11):2368–2383
12. Kim Y, Lee S, Lee Y, Park S, Park S, Paek JH et al (2021) The minimum-mortality estimated glomerular filtration rate percentile shifts upward in the aged population: a nationwide population-based study. Clin Kidney J 14(5):1356–1363
13. Cox HJ, Bhandari S, Rigby AS, Kilpatrick ES (2008) Mortality at low and high estimated glomerular filtration rate values: a ‘U’ shaped curve. Nephron Clin Pract 110(2):e67–72
14. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J (1991) HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84(1):129–139
15. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
16. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW et al (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53(4):766–772
17. HUSLAB-liikelaitos. (2020) Glomerulussuosonopeus, estimoitu, CKD-EPI-kaava. HUSLAB. Available from: [https://huslab.fi/ohjekirja/21218.html](https://huslab.fi/ohjekirja/21218.html) Accessed 1 Jun 2020
18. Stefansson VTN, Schei J, Jenssen TG, Melsom T, Eriksen BO (2016) Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study. BMC Nephrol. [https://doi.org/10.1186/s12882-016-0386-4](https://doi.org/10.1186/s12882-016-0386-4)
19. Maeda I, Hayashi T, Sato KK, Koh H, Harita N, Nakamura Y et al (2011) Cigarette smoking and the association with glomerular hyperfiltration and proteinuria in healthy middle-aged men. Clin J Am Soc Nephrol 6(10):2462–2469
20. Banack HR, Kaufman JS (2016) Estimating the time-varying joint effects of obesity and smoking on all-cause mortality using marginal structural models. Am J Epidemiol 183(2):122–129
21. Lin M, Su Q, Huang H, Zheng Y, Wen J, Yao J et al (2017) Alcohol consumption and the risk for renal hyperfiltration in the general Chinese population. Eur J Clin Nutr 71(4):500–505
22. Jhee JH, Nam KH, An SY, Cha M-U, Lee M, Park S et al (2018) Severe vitamin D deficiency is a risk factor for renal hyperfiltration. Am J Clin Nutr 108(6):1342–1351
23. Reboldi G, Verdecchia P, Fiorucci G, Beilin LJ, Eguchi K, Imai H et al (2019) Renal hyperfiltration defined by high estimated glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 120:419–428
24. Yoo KD, Yoon H-J, Hwang S, Heo NJ, Chin HJ, Yang SH et al (2017) Different association between renal hyperfiltration and mortality by sex. Nephrology 22(10):804–810
25. Donfrancesco C, Palleschi S, Palmieri L, Rossi B, Lo Noce C, Pannozzo F et al (2013) Estimated glomerular filtration rate, all-cause mortality and cardiovascular diseases incidence in a low risk population: the MATISS study. PLoS ONE 8(10):e78475

26. Eriksen BO, Løchen M-L, Arntzen KA, Bertelsen G, Eilertsen B-AW, von Hanno T et al (2014) Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population. Kidney Int 86(1):146–153

27. Sundin P-O, Udumyan R, Fall K, Montgomery S (2019) Grip strength modifies the association between estimated glomerular filtration rate and all-cause mortality. Nephrol Dial Transplant 34(10):1799–1801

28. Groop PH, Thomas MC, Moran JL, Wadén J, Thorn LM, Mäkinen VP et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58(7):1651–1658

29. Shimada Y, Nakasone Y, Hirabayashi K, Sakuma T, Koike H, Oguchi T et al (2020) Development of glomerular hyperfiltration, a multiphasic phenomenon. Am J Physiol Renal Physiol 319(6):F1037–F1041

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.